Search Results
Your search for ,ouT matches 5632 pages
Showing 3701 - 3750FDA Approves New Diagnostic Imaging Agent to Detect Recurrent Prostate Cancer
On May 27, the U.S. Food and Drug Administration (FDA) approved fluciclovine F-18 (Axumin), a radioactive diagnostic agent for injection. Fluciclovine F-18 is indicated for positron-emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated...
Colleagues Tip Their Hats to Allen S. Lichter, MD, FASCO
After serving as ASCO’s CEO for 10 years, Allen S. Lichter, MD, FASCO, is stepping down. Dr. Lichter, who has been an ASCO member since 1980, has served the Society in numerous capacities. Along with his distinguished career at ASCO, Dr. Lichter is a nationally recognized radiation oncologist,...
Surgical Oncologist Suzanne L. Topalian, MD, Shines at the Forefront of Groundbreaking Research in Cancer Immunotherapy
Nationally recognized surgical oncologist and researcher Suzanne L. Topalian, MD, had an early interest in the arts as well as science and decided to major in English upon entering Wellesley College in Wellesley, Massachusetts. “I wanted to keep all my options open, so I also enrolled in a pre-med...
Noted Gastrointestinal Oncologist Leonard Saltz, MD, Tempers Optimism With Reality and Factors Cost Into the Equation of Value in Cancer Care
Leonard Saltz, MD, was born in New York, New York, and reared in Westchester County, in the suburbs of the City. Terrance Archer, his high-school biology teacher, whom Dr. Saltz described as a “force of nature,” a wonderful human being, and a major role model, influenced his nascent curiosity in...
In Memoriam
The ASCO Post remembers the following specialists in oncology who passed away in 2015–2016. Please write to editor@ASCOPost.com to recognize and pay tribute to others in a future issue. Mark R. Green, MD January 3, 1945–February 23, 2015 “Few people have impacted cancer clinical research in the...
Physician-Researcher Carolyn Jean Presley, MD, Envisions Enhancing Geriatric Oncology
Carolyn Jean Presley, MD, a Robert Wood Johnson Foundation clinical scholar in medical oncology at the Yale Cancer Center, was born in Duluth, Minnesota, which hugs the north shore of Lake Superior, making it one of the nation’s coldest cities during its long winters. She grew up the middle child...
Lisa A. Newman, MD, MPH, FACS, FASCO, Balances Her Passions of Surgical Breast Oncology and Breast Cancer Disparity Research, Both Home and Abroad
Lisa A. Newman, MD, MPH, FACS, FASCO, Director of the Henry Ford Health System’s Breast Oncology Program, was born in New York, New York and, according to her, was blessed to have had parents who lived the African American version of the “American Dream.” Dr. Newman’s father was the son of...
A Pioneer in Lung Cancer Research, James L. Mulshine, MD, Champions Early Population-Based Lung Cancer Screening
A neighborhood doctor who told a good story was an unwitting mentor to internationally regarded lung cancer expert James L. Mulshine, MD. Born in Elizabeth, New Jersey, Dr. Mulshine relocated with his family to West Hartford, Connecticut, when he was a year old, and except for a brief hiatus on...
With a Strong Personal Connection to His Patients, Stephen P. Hunger, MD, Strives for a Cure for All Children With Leukemia
Nationally regarded children’s cancer specialist Stephen P. Hunger, MD, was born and reared in South Windsor, a small suburb of Hartford, Connecticut. Dr. Hunger grew up in the mid-1960s and 1970s, and in his words, “South Windsor was a pretty homogeneous experience. There wasn’t really any ethnic...
International Authority on Radiation Effects, Robert Peter Gale, MD, PhD, Has Pushed Scientific Boundaries in Search of Answers
It is widely reported that the first use of sargramostim (Leukine) in humans (granulocyte macrophage colony-stimulating factor; GM-CSF) was to treat victims of the Goiânia, Brazil, radiation accident in 1987. However, recently declassified documents show that sargramostim was first used a year...
Once a Vocational Nomad, Christine H. Chung, MD, Now Works to Promote Patient-Centered Care in Head and Neck Cancer
Christine H. Chung, MD, Chair of the Department of Head and Neck-Endocrine Oncology at Moffitt Cancer Center, Tampa, Florida, was born and reared in Seoul, Republic of Korea. Dr. Chung immigrated with her mother and two brothers to Los Angeles, where her family then resided. Dr. Chung did not speak ...
With an Illustrious Career in Breast Oncology, Daniel F. Hayes, MD, FASCO, Follows in the Footsteps of Giants as ASCO President-Elect
ASCO President-Elect Daniel F. Hayes, MD, FASCO, was born in Shelbyville, Indiana, a small city in the center of the state. “My dream was to become a high school basketball and track and field coach; my older brother wanted to be a doctor, and his ambitions also began in first grade,” revealed Dr....
Allen S. Lichter, MD, FASCO, Reflects on His Career Path and His Tenure as ASCO CEO, and Predicts a Bright Future for Radiation Oncology
Choosing a career path is one of life’s most challenging decisions, but for Allen S. Lichter, MD, FASCO, deciding to become a doctor was inherently natural. He was born with a great mentor and role model: his father. “I was born and raised in Detroit. My father was a general practitioner in...
Monitoring Survivors of Childhood Cancers for Late Effects of Treatment
This past January, ASCO held its inaugural Cancer Survivorship Symposium, which brought together the fields of medical oncology and primary care to address the critical need for coordinated care for cancer survivors. Among the presenters at the symposium was Smita Bhatia, MD, MPH, who gave the...
Occupational Therapy for Adults With Cancer: An Unmet Need
Adults with cancer are at high risk for functional limitations that would negatively affect their quality of life. Occupational therapy offers a range of supportive services, with the specific goal of helping these patients engage in life as independently as possible. To provide a better...
A Perilous Time for Refugees With Cancer
The numbers are difficult to fathom. According to a report by the United Nations High Commissioner for Refugees (UNHCR), in 2015, over 60 million people worldwide were forcibly displaced as a result of conflict, persecution, generalized violence, or human rights violations.1 Over 9 million of those ...
A Toolkit for Dealing With the Trauma of a Prostate Cancer Diagnosis
This year, an estimated 180,890 men in the United States will be diagnosed with prostate cancer; about 21,120 men die of the disease each year. On top of these sobering statistics, from screening to diagnosis and treatment, prostate cancer is fraught with controversy, creating untoward anxiety...
A Physician’s Guide to Pain and Symptom Management in Cancer Patients
Despite growing awareness and the existence of guidelines, undertreatment of cancer pain remains a persistent dilemma in the oncology community. Researchers from The University of Texas MD Anderson Cancer Center found that more than 33% of patients suffering from invasive cancer do not receive...
ASCO’s State Affiliate Council Improves Communication Between ASCO and Community Physicians
ASCO established a State Affiliate Council in 2012 consisting of representatives from each of the Society’s 48 state or regional oncology societies. The Council met on April 21–22 at ASCO headquarters in Alexandria, Virginia. The ASCO Post talked with Paul Celano, MD, FACP, President, Maryland/DC...
ASCO Past-President Anticipates a New Position With an Ongoing Goal of Advancing the Field of Oncology
After an extensive national search, Hartford HealthCare has appointed ASCO Past-President Peter Paul Yu, MD, FACP, FASCO, as the first Physician-in-Chief of the Hartford HealthCare Cancer Institute. As Physician-in-Chief, Dr. Yu will be responsible for working closely and collaboratively with...
Enhance Your Annual Meeting Experience With Attendee Resources
Next month, more than 30,000 oncology professionals will gather in Chicago for the 2016 ASCO Annual Meeting. This year’s theme, “Collective Wisdom: The Future of Patient-Centered Care and Research,” highlights the value of the combined knowledge of the global oncology community, spanning across...
Four Reasons to Use Social Media at the ASCO Annual Meeting
Join the discussion: Use #ASCO16 on Twitter to follow and participate in the conversation around the Annual Meeting in real time! During last year’s Annual Meeting, more than 12,400 individuals sent over 59,000 tweets, reaching an estimated 262 million people on Twitter. Tweets about the Meeting ...
ExteNET Trial of Neratinib: One Size Does Not Fit All in HER2-Positive Breast Cancer
Neratinib is an oral anti-HER2 tyrosine kinase inhibitor that has shown promising activity in the treatment of HER2-positive metastatic breast cancer.1 It differs from monoclonal antibodies such as trastuzumab (Herceptin) because, as a small molecule, neratinib blocks the ATP binding site on the...
Survey Finds Most Americans Unlikely to Enroll in Clinical Trials
According to a new survey of more than 1,500 consumers and nearly 600 physicians conducted on behalf of Memorial Sloan Kettering Cancer Center (MSK), only 35% of Americans indicated that they were “likely” to enroll in a clinical trial. Other studies have shown that only 4% of cancer...
Is Male Breast Cancer Overlooked in Clinical Trials?
Three and a half years ago, Oliver Bogler, PhD, a cancer biologist and Senior Vice President of Academic Affairs at the University of Texas MD Anderson Cancer Center, saw his personal and professional worlds collide. He received a cancer diagnosis—one that mirrored his wife’s. “Some might say that ...
Dr. Susan Love: Time to Address ‘Collateral Damage’ of Breast Cancer Treatment
The “collateral damage” of cancer treatment is a topic that is familiar to Susan Love, MD, MBA. As a breast cancer surgeon and chief visionary officer of Dr. Susan Love Research Foundation, she has learned much about the consequences of cancer treatment. But she came by an important aspect of her...
Expert Point of View: Mahmoud El-Tamer, MD
Mahmoud El-Tamer, MD, a breast surgeon at Memorial Sloan Kettering Cancer Center, New York, who moderated the session where the results were presented, pointed out that although the results were provocative, the selection of patients was “biased,” as they had already presented to a breast surgery...
Young Women Require Formal Assessment to Identify Breast Cancer Risk
Half of the young women presenting to an academic surgical breast practice would qualify for mammography screening starting at age 40. According to the newly updated guidelines, these young at-risk women may be missed, researchers reported at the 2016 American Society of Breast Surgeons (ASBS)...
ODAC Advises the FDA to Wait for Phase III Results for Rociletinib in Non–Small Cell Lung Cancer
The U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) met April 12 to consider a New Drug Application by Clovis Oncology for rociletinib, an investigational therapy for epidermal growth factor receptor (EGFR)-mutated non–small cell lung cancer (NSCLC) in patients...
New FDA Rule Prohibits Sale of E-Cigarettes to Anyone Under Age 18 and Requires Warning Labels
A new rule extending U.S. Food and Drug Administration (FDA) oversight to all tobacco products, including electronic cigarettes (e-cigarettes), and banning the sale of these products to anyone under the age of 181 was hailed as a major advanced by many leaders of medical and health organizations....
White Knuckling
The ASCO Post is pleased to reproduce installments of the “Art of Oncology” as published previously in the Journal of Clinical Oncology (JCO). These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
William G. Kaelin, Jr, MD, Receives AACR Princess Takamatsu Award
William G. Kaelin, Jr, MD, Chair of the Executive Committee for Research at Dana-Farber Cancer Institute, received the 10th annual Princess Takamatsu Award for “novel and significant work” in cancer from the American Association for Cancer Research (AACR). Dr. Kaelin, who is Professor of Medicine...
How Immunotherapy Is Revolutionizing Cancer Care
More than 100 years after William B. Coley, MD, used bacterial toxins to goad the immune system into recognizing cancer cells as foreign to the body and mount an immune response to go after and kill them, the recognition of immunotherapy as a powerful anticancer therapy is finally being...
Meta-analysis of Breast Cancer Studies Demonstrates Value of Pathologic Complete Response
In a meta-analysis of neoadjuvant studies totaling over 18,000 patients, achievement of pathologic complete response was associated with significantly reduced disease recurrence and mortality across the various breast cancer subtypes. Laura Spring, MD, a senior medical oncology fellow at...
Maximizing Cancer Cure: How Do We Get There?
Is cancer really “curable,” and if so, how? For a “Cancer Dialogue” held during the 2016 American Association of Cancer Research (AACR) Annual Meeting, half a dozen stellar participants from the research, industry, regulatory, and advocacy communities convened to debate the topic. The ASCO Post was ...
The Arrival of Generic Imatinib Into the U.S. Market: An Educational Event
Imatinib mesylate (Gleevec), a Bcr-Abl tyrosine kinase inhibitor, is approved therapy for chronic myeloid leukemia (CML) in the United States. Imatinib is a miraculous drug that results in a normal functional lifespan in most patients with CML who can afford and comply with the treatment and who ...
Pembrolizumab Survival Benefit Proves Durable in Patients With Advanced Melanoma
With new immunotherapies available for the treatment of advanced melanoma, an important question is how best to combine and sequence them. Long-term follow-up from the KEYNOTE-001 trial suggests that pembrolizumab (Keytruda) can improve survival in newly diagnosed patients and in those treated...
What ASCO Can Do for You—and for Our Patients
This is an exciting time to be an oncologist. I often say I wish I were 30 again and just starting out in my oncology career. Never before have we had such sophisticated technology for evaluation of the tumor or such a potent arsenal of targeted and effective therapies to treat cancer. Further, the ...
Oncology and Diplomacy in the Middle East
The Middle East is a vast region comprised largely of developing nations with complicated sociopolitical challenges, violent internecine disputes, and deeply fragmented health-care systems. Not surprisingly, the region’s suboptimal health care contributes to the late diagnosis and poor survival...
In Celebration of a Remarkable Career at ASCO
In March, ASCO announced that Allen S. Lichter, MD, FASCO, was stepping down as Chief Executive Officer (CEO) at the end of June, ending his 10-year tenure as head of the Society and the Conquer Cancer Foundation of ASCO. Clifford A. Hudis, MD, FACP, Chief of Breast Medicine Service and Vice...
Use of Complementary and Alternative Medicine Affects Breast Cancer Chemotherapy Initiation
Women with early-stage breast cancer for whom chemotherapy was indicated and who used dietary supplements and multiple types of complementary and alternative medicine were less likely to start chemotherapy than nonusers of alternative therapies, according to research led by Heather Greenlee, ND,...
AUA 2016: IsoPSA, a Novel, Structure-Based Biomarker Test for Prostate Cancer, Explored in a Multicenter Prospective Trial
A promising new test is detecting prostate cancer more precisely than current tests by identifying molecular changes in the prostate-specific antigen (PSA) protein, according to Cleveland Clinic research presented at the 111th Annual Scientific Meeting of the American Urological Association (AUA)...
AUA 2016: Relationship Between Testosterone Therapy and Prostate Cancer Explored
Men with low levels of the male sex hormone testosterone need not fear that testosterone replacement therapy will increase their risk of prostate cancer. This is the finding of an analysis of more than a quarter-million medical records of mostly white men in Sweden, research led by investigators at ...
Some Diagnostic Variability in Interpreting Breast Biopsy Slides
Pathologists disagree about 8% of the time when interpreting a single breast biopsy slide, with more overinterpretation than underinterpretation in discordant cases, according to an analysis combining results from the B-Path (Breast Pathology) study with data on the prevalence of breast cancer...
Cancer Stole My Identity
In 1997, just 6 weeks after giving birth to my second child, I started having fevers and night sweats and my lymph nodes were swollen. I’m a physician, so I knew something was wrong and that my symptoms were unrelated to having just given birth. I had a blood test, and a biopsy was performed on one ...
‘So How Long Do I Have?’
Imagine accidentally falling off an abyss. One simply cannot fully understand the gravity of the situation! You might skip a beat thinking about it while sitting in a chair in your living room, if you have tons of empathy, as you try to get into the shoes that are flailing for survival. But there...
A History of Medical Care for the Dying
In 2006, palliative care became a board-certified subspecialty of internal medicine, with specialized fellowships for physicians interested in the field. Despite its formal integration into best practices medical care, about 70% of Americans describe themselves as “not at all knowledgeable” about ...
Inspirational Stories for Cancer Survivors
Surveys indicate that cancer survivors have varying desires regarding the kind of support they want. Some patients find support groups very helpful as they deal with the host of issues in survivorship. Others want to distance themselves from the “world of cancer.” Studies also show that...
Recurrences Observed in More Than 50% of Inadequately Treated Patients With Ductal Carcinoma in Situ
A mid much debate about the potential for overly aggressive treatment of ductal carcinoma in situ comes a study that gives one pause. According to research presented at the 17th Annual Meeting of the American Society of Breast Surgeons, more than half of all women with ductal carcinoma in situ that ...
Interactive, Focused Learning at the ASCO Annual Meeting
The ASCO Annual Meeting, which will be held June 3–7, 2016, in Chicago, brings together more than 30,000 oncology professionals from around the world to learn about and discuss the latest therapies, treatment modalities, research, and controversies in the field. Attendees are able to personalize...
